Shabani Mahdi, Asgarian Omran Hossein, Farsangi Mohammad Hojjat, Vossough Parvaneh, Sharifian Ramazan A, Toughe Gholam R, Razavi Seyed Mohsen, Khoshnoodi Jalal, Jeddi-Tehrani Mahmood, Rabbani Hodjatallah, Shokri Fazel
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Avicenna J Med Biotechnol. 2011 Jul;3(3):119-25.
It has recently been shown that ROR1, a member of the receptor tyrosine kinase family, is overexpressed in leukemic B cells of Chronic Lymphocytic Leukemia (CLL) and a subset of Acute Lymphoblastic Leukemia (ALL). In this comparative study the expression profile of ROR1 mRNA was investigated in Iranian patients with CLL and Acute Myelogenous Leukemia (AML) and the results were compared with those previously reported in our Iranian ALL patients. RT-PCR was performed on bone marrow and/or peripheral blood samples of 84 CLL and 12 AML patients. CLL samples were classified into immunoglobulin heavy chain variable region (IGHV) gene mutated (n = 55) and unmutated (n = 29) and also indolent (n = 42) and progressive (n = 39) subtypes. ROR1 expression was identified in 94% of our CLL patients, but none of the AML patients expressed ROR1. No significant differences were observed between different CLL subtypes for ROR1 expression. Taken together the present data and our previous results on ROR1 expression in ALL, our findings propose ROR1 as a tumor-associated antigen overexpressed in a large proportion of lymphoid (CLL and ALL), but not myeloid (AML) leukemias. Expression of ROR1 seems to be associated to lineage and differentiation stages of leukemic cells with a potential implication for immunotherapy.
最近研究表明,受体酪氨酸激酶家族成员ROR1在慢性淋巴细胞白血病(CLL)的白血病B细胞和一部分急性淋巴细胞白血病(ALL)中过表达。在这项比较研究中,对伊朗CLL和急性髓性白血病(AML)患者的ROR1 mRNA表达谱进行了研究,并将结果与我们之前报道的伊朗ALL患者的结果进行了比较。对84例CLL患者和12例AML患者的骨髓和/或外周血样本进行了逆转录聚合酶链反应(RT-PCR)。CLL样本被分为免疫球蛋白重链可变区(IGHV)基因突变型(n = 55)和未突变型(n = 29),以及惰性(n = 42)和进展性(n = 39)亚型。在我们94%的CLL患者中检测到ROR1表达,但所有AML患者均未表达ROR1。不同CLL亚型之间的ROR1表达未观察到显著差异。综合目前的数据以及我们之前关于ALL中ROR1表达的结果,我们的研究结果表明ROR1是一种肿瘤相关抗原,在大部分淋巴系白血病(CLL和ALL)中过表达,但在髓系白血病(AML)中不表达。ROR1的表达似乎与白血病细胞的谱系和分化阶段相关,对免疫治疗可能具有潜在意义。